A dose-escalating phase I study with valproic acid (VPA) in patients (pts) with advanced cancer
Akin Atmaca(Heidelberg University), E. Jaeger(Krankenhaus Nordwest), Antje Neumann(Krankenhaus Nordwest), Martin Göttlicher, Alexander Maurer, Emily C. Martin(St. Michael's Hospital), Salah-Eddin Al-Batran(Goethe University Frankfurt), Ingrid Bartsch(Krankenhaus Nordwest), A. Knuth(University Hospital Zurich), Thorsten Heinzel(Friedrich Schiller University Jena)
Cited by 4
Related Papers
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
|Journal of Clinical Oncology|2008|784
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
|Proceedings of the National Academy of Sciences|2000|427
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
|The Lancet Oncology|2023|336
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
|New England Journal of Medicine|2019|320